Up next

Autoplay

Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC). Eng says the combination came about through medical professional's use of bevacizumab in the frontline as a treatment for mCRC, leading one Italian research group to start the TRIBE trial.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Show more
0 Comments sort Sort By

Up next

Autoplay